Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
Volume 2.23M
Average 1.99M
MIST Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Milestone Pharmaceuticals Inc.NASDAQ: MIST
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue remains negative
Q1 FY2026 revenue was $238K, compared with $0 a year earlier. Trailing-twelve-month revenue was $1.78M. Over 3 fiscal years it compounded at -32.4% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $4.89M (+216.4%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $238K-84.6% QoQ
- Last fiscal yearDec 2025
- $1.55M— YoY
- LTMMar 2026
- $1.78M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +216.4% | — |
| 3-year CAGR | -32.4% | +210.5% | +242.8 pp |
| 5-year CAGR | +149.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 1.55M USD
- Year-over-year change
- —
- 4-year CAGR
- -43.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.55M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 1M | -80.0% |
| FY2022 | 2022-12-31 | 5M | -66.7% |
| FY2021 | 2021-12-31 | 15M | — |
Revenue vs competitors
How MIST compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Over three fiscal years its annual growth of -32.4% compares with a peer median of -24.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $3.17M USD | +164.1% | — | |
| FY2025 | €2.79M EUR | -77.9% | -63.6% | |
| LTM Mar 2026 | $1.78M USD | — | -32.4% | |
| LTM Mar 2026 | $525K USD | -10.7% | +15.4% | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | CHF 0 CHF | -100.0% | — | |
| LTM Mar 2026 | $0 USD | — | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $0 USD | — | — |
| Peer median (excluding MIST) | — | -44.3% | -24.1% | |
Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 15M | 5M | 1M | 0 | 1.55M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 114K |
| Gross Profit | 15M | 5M | 1M | 0 | 1.43M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 92.6% |
| Research & Development | 38.67M | 39.83M | 31.05M | 14.36M | 18.11M |
| Selling, General & Admin | 19.4M | 24.81M | 31.05M | 27.75M | 17.27M |
| Operating Expenses | 58.07M | 64.64M | 62.1M | 42.1M | 63.92M |
| Depreciation & Amortization | 93K | 89K | 92K | 105K | 114K |
| EBITDA | (42.76M) | (58.3M) | (57.04M) | (37.83M) | (59.45M) |
| EBITDA Margin | -285.1% | -1166.0% | -5703.9% | — | -3845.5% |
| Operating Income | (43.07M) | (59.64M) | (61.1M) | (42.1M) | (62.49M) |
| Operating Margin | -287.2% | -1192.8% | -6109.8% | — | -4041.7% |
| Interest Income | 220K | 1.25M | 3.97M | 4.16M | 2.92M |
| Interest Expense | 0 | 0 | 2.55M | (3.58M) | 3.84M |
| Other Income / Expenses | 220K | 1.25M | 1.41M | 583K | (918K) |
| Income Before Tax | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.4M) |
| Pre-Tax Margin | -285.7% | -1167.8% | -5968.5% | — | -4101.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | (345K) |
| Net Income | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.06M) |
| Net Margin | -285.7% | -1167.8% | -5968.5% | — | -4078.8% |
| EPS (Basic) | (1.02) | (1.35) | (1.39) | (0.67) | (0.75) |
| EPS (Diluted) | (1.02) | (1.35) | (1.39) | (0.67) | (0.75) |
| Weighted Avg Shares | 41.83M | 42.45M | 42.96M | 62.21M | 83.88M |
| Weighted Avg Shares (Diluted) | 41.83M | 42.45M | 42.96M | 62.21M | 83.88M |
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
Intrinsic Alpha fair value
Locked
Current Price
$0.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.